trending Market Intelligence /marketintelligence/en/news-insights/trending/TVM_GsAj5lngPN4Q9HQKcg2 content esgSubNav
In This List

Roche's $4.3B tender offer for Spark Therapeutics further extended

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roche's $4.3B tender offer for Spark Therapeutics further extended

Roche Holding AG is again extending the tender offer period to acquire all shares of Philadelphia-based Spark Therapeutics Inc. for $114.50 apiece, or $4.3 billion in cash.

The offer will now expire 5 p.m. ET on Oct. 1, unless further extended. The extension was to give U.S. Federal Trade Commission and the U.K. Competition and Markets Authority more time to complete their regulatory review of the transaction.

Basel, Switzerland-based Roche previously extended the offer period to Sept. 3 from July 31. The company already extended the offer period several times from the initial April 3 deadline.

As of 5 p.m. ET on Aug. 30, about 9,284,005 Spark shares had been validly tendered and received and not validly withdrawn, representing about 24.1% of the gene-therapy maker's outstanding common shares.

Completion of the tender offer is conditional upon closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Act, and the tender of the majority of Spark's shares.

MacKenzie Partners Inc. is acting as information agent for the tender offer. Citibank NA is the depository for the offer.